Cargando…

Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma

BACKGROUND: CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) accounts for 5–10% of DLBCL cases and has poor patient outcomes. However, most studies on CD5+ DLBCL were performed in Japanese patients and only few data are available for Korean population. In this study, we investigated the clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyun-Young, Jang, Mi-Ae, Kim, Hee-Jin, Kim, Seok Jin, Kim, Won Seog, Kim, Sun-Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641511/ https://www.ncbi.nlm.nih.gov/pubmed/29043234 http://dx.doi.org/10.5045/br.2017.52.3.193

Ejemplares similares

Differences in mutational signature of diffuse large B‐cell lymphomas according to the primary organ
por: Koh, Hyun‐Hee, et al.
Publicado: (2023)

Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors
por: Na, Hee Young, et al.
Publicado: (2019)

De novo CD5 Positive Diffuse Large B-cell Lymphomas with Bone Marrow Involvement in Korean
por: Kong, Sun-Young, et al.
Publicado: (2004)

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
por: Yi, Jun Ho, et al.
Publicado: (2023)

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain
por: Cho, Junhun, et al.
Publicado: (2022)

Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism
por: Lim, Sung Hee, et al.
Publicado: (2016)

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
por: Park, Ha Young, et al.
Publicado: (2016)

Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry
por: Yi, Hyeon Gyu, et al.
Publicado: (2013)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

A Case of B-cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma in a Korean Child
por: Ahn, Jeong Yeal, et al.
Publicado: (2012)

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study
por: Yhim, Ho-Young, et al.
Publicado: (2010)

FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma
por: Ryu, Kyung Ju, et al.
Publicado: (2016)

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma
por: Lee, Hyunjee, et al.
Publicado: (2023)

Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas
por: Shin, Sang-Yong, et al.
Publicado: (2016)

Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma
por: Lee, Ha-young, et al.
Publicado: (2014)

The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen
por: Kim, Yundeok, et al.
Publicado: (2014)

Simultaneous Occurrence of Angioimmunoblastic T-cell Lymphoma and Plasma Cell Leukemia
por: Jang, Mi-Ae, et al.
Publicado: (2015)

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jinchul, et al.
Publicado: (2023)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2023)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
por: Yhim, Ho-Young, et al.
Publicado: (2020)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma
por: Hong, Junshik, et al.
Publicado: (2017)

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2023)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party
por: Suh, Cheolwon, et al.
Publicado: (2013)

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab–CHOP
por: Hong, Jung Yong, et al.
Publicado: (2017)

Novel Mutations in CEBPA in Korean Patients with Acute Myeloid Leukemia with a Normal Karyotype
por: Kim, Sollip, et al.
Publicado: (2012)

Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system
por: Yoon, Sang Eun, et al.
Publicado: (2020)

Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance
por: Suh, Koung Jin, et al.
Publicado: (2019)

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
por: Cho, Inju, et al.
Publicado: (2020)

Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma
por: Jeong, Sun Young, et al.
Publicado: (2023)

Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study
por: Hur, Joon Young, et al.
Publicado: (2020)

Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm
por: Yoon, Nara, et al.
Publicado: (2017)

Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis
por: Park, Silvia, et al.
Publicado: (2015)

Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update
por: Hong, Jung Yong, et al.
Publicado: (2016)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
por: Choi, Soyeon, et al.
Publicado: (2022)

The prognostic significance of CD11b(+)CX3CR1(+) monocytes in patients with newly diagnosed diffuse large B-cell lymphoma
por: Yhim, Ho-Young, et al.
Publicado: (2017)

Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients
por: Yoon, Jae-Ho, et al.
Publicado: (2015)

Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma
por: Choi, Chang Hwan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_q6bdsqo6k10r920tnb075iq1go